2 min read
JHL Biotech, Inc. and Selexis SA Form Biologic Drug Development Alliance to Serve the Biopharmaceutical Industry
Strategic Alliance to Provide Seamless Services from Cell Line Development to cGMP Manufacturing of Biologic Drugs
Admin
.png?width=1800&height=600&name=MicrosoftTeams-image%20(82).png)
1 min read
Selexis SA Sells Rights to Royalty Payments for More Than 15 Biologic Development Programs to Ligand Pharmaceuticals
Admin: Apr 30, 2013 12:00:00 AM
Funding to Expand the SUREtechnology Platform™
1 min read
Selexis Lubris Partnership Advances Difficult-to-Express Protein Towards Clinic
Admin: Jun 27, 2012 12:00:00 AM
Lubris Achieves Over Gram per Liter of Recombinant Human Lubricin Using Selexis SUREtechnology Platform
2 min read
Irvine Scientific Launches BalanCD CHO SLX A Culture Media Developed for the Selexis SURE CHO-M Cell Line
Admin: Jun 6, 2012 12:00:00 AM
The New Media Improves SURE CHO-M Productivity
2 min read
Selexis SA and Fusion Antibodies Services Form Partnership to Speed Therapeutic Monoclonal Antibody Development
Admin: May 23, 2012 12:00:00 AM
Geneva, Switzerland, May 23, 2012 (PRNewswire) – Selexis SA, a global life sciences company for drug discovery, cell line development and scale-up to…
1 min read
ADIENNE Pharma & Biotech Signs Service Agreement with Selexis for the Development of a Novel Fully Human Mini-Antibody
Admin: May 15, 2012 12:00:00 AM
Geneva, Switzerland, May 15, 2012 (PRNewswire) – Selexis SA, a global life sciences company for drug discovery, cell line development and scale-up to…
1 min read
CSL Limited Signs Commercial License Agreement with Selexis SA
Admin: Jul 26, 2011 12:00:00 AM
CSL Limited Signs Commercial License Agreement with Selexis SCSL Limited will use Selexis Technologies for Development of Therapeutic Antibody
2 min read
Selexis SA and the University of Lausanne Announce the Complete Sequencing of the Selexis SURE CHO-M Genome
Admin: Mar 23, 2011 12:00:00 AM
Major Milestone Will Speed Regulatory Filings for Recombinant Protein Therapeutics and Monoclonal Antibodies Developed with the Proprietary Selexis…
1 min read
Selexis and Neogenix Oncology Execute Commercial License Agreement
Admin: Jan 5, 2011 12:00:00 AM
Geneva, Switzerland, January 5, 2011 Selexis SA, a Swiss-based biotechnology company offering technologies and services to enable improved drug…